MetaCap

CG Oncology (CGON) vs Immunovant (IMVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CG Oncology (CGON) has outperformed Immunovant (IMVT) over the past year, gaining 87.3% versus a gain of 40.6%. CG Oncology is the larger company by market cap ($7.10 billion vs $6.57 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGON+87.25%IMVT+40.64%
+105%+44%-18%
Nov 21, 20251 yearNov 20, 2026
CGON+126.86%IMVT-16.94%
+137%+32%-73%
Jan 22, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGON versus IMVT key metrics
MetricCGONIMVT
Share price$79.47$31.77
Market cap$7.10B$6.57B
1-day change-2.97%-2.31%
YTD return+91.40%+24.98%
1-year return+87.25%+40.64%
5-year return—+308.88%
EPS (TTM)$-2.76$-2.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.04M—
Revenue growth (YoY)+254.70%—
Net income (latest FY)$-161.00M$-505.61M
Operating margin-4722.13%—
Net margin-3985.02%—
52-week high$93.95$45.42
52-week low$37.01$21.93
Distance from 52-week high-15.41%-30.05%
Analyst consensusstrong_buybuy
Avg. price target upside+38.03%+53.07%
Average volume1.24M1.42M
Shares outstanding89.32M206.95M
Employees142315
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGON has outperformed IMVT by 46.6 percentage points over the past year.

About CG Oncology

CGON stock →

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees

About Immunovant

IMVT stock →

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees

CGON vs IMVT FAQ

Which is bigger, CG Oncology or Immunovant?

CG Oncology (CGON) is larger, with a market capitalization of $7.10B compared with $6.57B for Immunovant (IMVT).

Which stock has performed better over the past year, CGON or IMVT?

CGON returned +87.25% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.

Are CG Oncology and Immunovant in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons